Reunion Neuroscience Inc
Change company Symbol lookup
Select an option...
REUN Reunion Neuroscience Inc
APTO Aptose Biosciences Inc
JNJ Johnson & Johnson
AVGO Broadcom Inc
GILD Gilead Sciences Inc
LLY Eli Lilly and Co
ABBV Abbvie Inc
CIEN Ciena Corp
TEAM Atlassian Corp
MRO Marathon Oil Corp
Go

Health Care : Health Care Providers & Services | Small Cap Growth
Based in Canada
Company profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Price
Delayed
$1.28
Day's Change
0.005 (0.39%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.28
Day's Low
1.25
Volume
(Heavy Day)

Today's volume of 1,413 shares is on pace to be much greater than REUN's 10-day average volume of 8,658 shares.

1,413

Company Profile

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
6.57x
Price/Book (MRQ)
0.53x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
47.3K
Previous Month
52.2K
Percent of Float
0.57%
Days to Cover
4.2470 Days

Share Information

REUN is in a share class of common stock
Float
8.3M
Shares Outstanding
11.6M
Institutions Holding Shares
27
15.49%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

  • 30 Duncan Street, Suite 401
  • Toronto, ON M5V 2C3
  • Canada

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.